1月26日， 天津市第十八届人民代表大会第四次会议在天津礼堂开幕。 记者 佟郁 摄 同日提交大会审议的《天津市国民经济和社会发展第十五个五年规划纲要(草案)》亦提出，将依托先进 医用材料与医疗器械全国重点实验室、脑机交互与人机共融海河实验室、天津市脑机接口创新中心等平 台，联合南开大学、天津大学等单位，积极争创脑机接口领域国家技术创新中心。 根据上述规划草案，天津将加快脑机接口、类脑芯片、类脑计算机关键算法、人机交互底层核心器件等 研发与成果转化，推动脑机交互技术在医疗科研、运动与感知辅助、游戏娱乐、学习教育、智能家居等 领域的应用，加速推动一批重大科技成果落地转化。(完) 中新网天津1月26日电 (记者 周亚强)天津市第十八届人民代表大会第四次会议26日开幕，市长张工作政 府工作报告(下称"报告")。报告提出，天津将争建国家脑机接口技术创新中心，在关键技术突破上作 出"天津创新贡献"。 报告称，天津将积极共建北京(京津冀)国际科技创新中心，聚焦本地优势与需求，畅通与驻津央院央 所、高校研发平台等"握手"通道，推进科研设备共享、设施共同、团队梯次共建，支持"六链五群"重点 企业与战略科技力量加强产学研合作。 ...

Market Performance - The Hong Kong stock market showed mixed performance with the Hang Seng Index up by 0.06% closing at 26,765.52 points, while the Tech Index fell by 1.24% to 5,725.99 points, and the National Enterprises Index decreased by 0.15% to 9,147.21 points [1][2]. Sector Performance - Traditional cyclical stocks such as oil, coal, and non-ferrous metals performed strongly, indicating a shift in market focus towards value assets. In contrast, previously popular sectors like commercial aerospace and brain-computer interface technologies experienced a pullback [2][11]. Oil Sector - Oil stocks saw significant gains, with China National Offshore Oil Corporation (CNOOC) rising by 4.01%, China Petroleum & Chemical Corporation (Sinopec) increasing by 3.68%, and China Oilfield Services Limited up by 3.23%. This strength is attributed to a recent extreme cold wave in North America, which caused a 63% spike in U.S. natural gas prices from January 20 to 22, subsequently boosting prices of light hydrocarbons and supporting domestic petrochemical prices [4][5]. Coal Sector - Coal stocks also showed robust performance, with Mongolian Energy up by 5.80%, China Shenhua Energy rising by 4.42%, and China Qinfa up by 3.74%. The increase in coal prices is linked to heightened demand due to cold weather, with daily coal output from the Bohai Rim ports averaging 1.682 million tons, a week-on-week increase of 14.2 tons or 9.19% [6][7]. Non-Ferrous Metals Sector - Non-ferrous metal stocks were active, with Rusal rising by 12.31%, China Nonferrous Mining increasing by 9.87%, and Chifeng Jilong Gold Mining up by 7.44%. Citigroup's report indicates a structural bull market in aluminum, predicting a 61,000-ton structural deficit by early 2026 and raising the price target for aluminum from $2,950 to $3,400 per ton [8][9]. Gold Market - Morgan Stanley's research indicates that gold prices have surpassed their forecast of $4,750 per ounce for the second half of the year, with expectations of further increases due to geopolitical risks, central bank purchases, and ETF inflows. A bullish scenario suggests a target price of $5,700 per ounce for the second half [10]. Weakness in Tech Sectors - Commercial aerospace stocks faced collective declines, with Asia Pacific Satellite down by 11.53%, Goldwind Technology down by 7.14%, and JunDa Co. down by 6.56%. This adjustment is attributed to short-term profit-taking pressures [11]. Brain-computer interface stocks also showed weakness, with Nanjing Panda Electronics down by 6.15% and Brainstorming Technology down by 5.35%, partly due to a recent share placement announcement [13][14]. Individual Stock Movements - Zhizhuo (02513.HK) surged by 13.02% following a significant increase in subscription service users after the launch of its flagship model GLM-4.7, indicating strong market interest in its AI capabilities [15]. Lao Pu Gold (06181.HK) rose by 7.80% due to increased customer traffic during a promotional event, with expectations of substantial revenue growth during the upcoming Spring Festival [16].

脑机接口赛道风口正盛，相关医械企业也开始"抢跑"。 其中，侵入式与半侵入式脑机接口主要应用于临床诊疗和科研领域，而非侵入式脑机接口系统主要应用 于智能健康和教育等消费场景。 市场近日传闻称，脑机接口企业强脑科技（BrainCo）以保密形式向港交所提交IPO申请，由中金公司与 瑞银集团联合保荐。 就此，21世纪经济报道记者通过官网联系方式向强脑科技方面求证，电话未被接听，采访邮件截至发稿 也暂未收到回复。若消息属实，强脑科技有望成为"杭州六小龙"中率先登陆资本市场的企业。 公开资料显示强脑科技成立于2015年，是一家专注于非侵入式脑机接口技术的硬科技企业，聚焦神经信 号采集、解码算法及智能仿生设备研发。其产品覆盖医疗健康、教育及消费级交互等领域，是国内较早 推进商业化的团队。 在递表传闻前不久，强脑科技刚完成新一轮融资。1月6日，公司宣布完成约20亿元人民币的融资，由 IDG资本、华登国际领投，投后估值超过13亿美元，被视为其上市进程中的关键一环。 华南某一级机构医疗行业分析师向21世纪经济报道记者表示，从消息传出时机来看非常微妙，一方面是 脑机接口概念在市场被热炒，另一方面是资方的退出通道越来越收紧，未来公司 ...

Core Insights - The article discusses the evolving landscape of exhibition design in Shanghai, emphasizing the increasing sophistication and high-end nature of brand experiences as the city solidifies its status as a global metropolis [1] - By 2026, the exhibition design industry in Shanghai is expected to be driven by digitalization, immersive experiences, and sustainability, leading to a new competitive environment [1] Industry Development Trends and Evaluation Criteria - Exhibition design in 2026 transcends traditional decoration, integrating cutting-edge technologies such as digital twins, extended reality (XR), and artificial intelligence [2] - Key evaluation criteria for outstanding exhibition design firms include strategic understanding and narrative ability, integration of technology and art, project execution and management, and sustainable and forward-thinking design [4] Evaluation of Outstanding Exhibition Design Firms in Shanghai - Yima Vision (Beijing) Cultural Media Co., Ltd. is recognized for its customized solutions for Fortune 500 companies, showcasing strong integration and innovation capabilities through projects like a digital twin system for a leading energy and chemical group [5] - Black Bubble Architectural Decoration Design Co., Ltd. focuses on commercial spaces and brand experience stores, utilizing unique spatial forms and lighting to convey brand values [6] - Note Decoration Design Engineering Co., Ltd. has extensive experience in museums and large corporate exhibitions, emphasizing content-driven design and effective information communication [8] - Huace Architectural Design Firm integrates urban and architectural perspectives into exhibition design, focusing on large public projects [8] - Yipin Display Design Co., Ltd. specializes in small to medium-sized commercial exhibitions, offering flexible and cost-effective solutions [8] - Jingjie Environmental Art Design Co., Ltd. excels in cultural theme exhibitions and tourist centers, translating regional cultural elements into modern design [8] Common Characteristics of Successful Projects - Successful exhibition designs shift from mere display to interactive experiences, fostering two-way dialogue between brands and audiences [9] - Data-driven dynamic spaces are becoming prevalent, particularly in technology and finance sectors, enhancing the credibility and freshness of displayed content [9] - Modular and sustainable design is gaining traction, allowing for easy updates and incorporating eco-friendly materials and intelligent energy management [9][10] - Integration of online and offline experiences is essential, with virtual exhibitions and interactive applications extending the lifecycle of displays [10] Conclusion - The exhibition design market in Shanghai in 2026 is characterized by professional specialization and cross-disciplinary integration, catering to diverse corporate needs [10] - Companies like Yima Vision demonstrate irreplaceable value for large groups seeking to convey complex strategic values, while local firms offer rich and high-quality options for brand expression and cultural transmission [10] - Future advancements in technologies such as AI-generated content and brain-computer interfaces are expected to transform exhibition forms and interactions, with firms that understand business essence and human needs leading the market [10]

Core Viewpoint - Cathay Pacific Haitong continues to recommend innovative pharmaceuticals and medical devices, highlighting the high growth potential in the innovative drug sector and the gradual realization of performance in Biopharma/Biotech [1] Group 1: Investment Recommendations - The company recommends Pharma, which is expected to see a revaluation due to its value potential [1] - Biopharma/Biotech is highlighted for its innovative pipelines and performance entering a growth phase [1] - CXO and upstream pharmaceutical sectors are recommended due to their benefits from innovation and recovery in market conditions [1] Group 2: Medical Devices and Consumer Healthcare - Medical devices are recommended, particularly those benefiting from engineering talent and successful overseas expansion [1] - The consumer healthcare sector is noted for its gradual recovery [1] Group 3: Policy Support and Market Catalysts - Recent supportive policies include the National Healthcare Security Administration's release of guidelines for pricing projects related to surgical and therapeutic auxiliary services, which are expected to benefit innovative surgical projects [1] - The medical device sector is experiencing frequent catalysts, with investment opportunities in overseas expansion, brain-computer interfaces, and AI healthcare [1] Group 4: ETF and Index Information - The Cathay Pacific Medical ETF (159377) tracks the innovative pharmaceutical index (399275), which has a daily price fluctuation limit of 20% [1] - This index focuses on innovative biopharmaceuticals, including companies engaged in biotechnology, genetic engineering, and new drug development, reflecting the overall performance of related listed companies [1] - The index emphasizes high growth potential and innovation capability, aiming to represent the development trends in the relevant industry [1]

Group 1 - The A-share medical sector weakened on January 26, with AI medical and brain-computer interface concepts leading the decline, as Meien Health dropped by 6% and Weining Health and Sanbo Brain Science fell over 5% [1] - The largest medical ETF in the market (512170) declined by more than 1.6%, losing its half-year line, with real-time transactions exceeding 600 million yuan [1] - Despite the overall decline, the medical ETF (512170) showed high-frequency premiums in the market, indicating active buying interest, with a weekly increase in positions exceeding 813 million yuan [1] Group 2 - CITIC Securities recently published a weekly review of the pharmaceutical industry, indicating that policy impacts will eventually clear, and companies will gradually recover after strategic adjustments, with the medical device sector undergoing dual recovery in valuation and performance [3] - The report suggests increasing allocation to the medical device sector by 2026, with major investment opportunities arising from performance recovery, overseas expansion, brain-computer interfaces, and AI medical technologies, potentially leading to multi-bagger stocks in a tech bull market [3] - The CXO sector is experiencing rapid growth due to advancements in ADC and peptide drugs, with increasing demand for related CXO services, and segments like small nucleic acids and CGT are expected to develop quickly [3] Group 3 - The largest medical ETF (512170) has a fund size of 26.8 billion yuan, making it the largest in the market among medical ETFs [3] - The medical ETF and its linked fund (012323) cover 12 AI medical and brain-computer interface concept stocks, with over 50% weight in medical devices and nearly 25% in CXO [3] - For those interested in Hong Kong stock medical opportunities, the Hong Kong Stock Connect Medical ETF (159137) focuses on medical innovation, gathering core leaders in various pharmaceutical fields, including medical devices, AI medical, CXO, and innovative drugs [3]

Group 1 - The A-share medical sector weakened on January 26, with AI medical and brain-computer interface concepts leading the decline, as Meien Health dropped by 6% and Weining Health and Sanbo Brain Science fell over 5% [1][6] - The largest medical ETF in the market (512170) fell by more than 1.6%, losing its half-year line, with real-time transactions exceeding 600 million yuan [1][6] - Notably, the medical ETF (512170) showed high-frequency premiums in the market, indicating active low-buying funds, with a weekly increase of over 813 million yuan [1][6] Group 2 - CITIC Securities recently published a weekly review of the pharmaceutical industry, indicating that policy impacts will eventually clear, and corporate strategic adjustments will lead to gradual recovery, particularly in the medical device sector, which is undergoing dual recovery in valuation and performance [3][8] - The report suggests increasing allocation to the medical device sector by 2026, with main investment opportunities arising from performance recovery, overseas expansion, brain-computer interfaces, and AI medical technologies, potentially leading to multi-fold stock growth in a tech bull market [3][8] - The CXO sector is experiencing rapid growth due to advancements in ADC and peptide drugs, with increasing demand in related fields such as small nucleic acids and CGT, indicating long-term growth potential [3][8] Group 3 - The medical ETF (512170) has a fund size of 26.8 billion yuan, making it the largest among medical ETFs in the market [3][8] - The ETF covers over 50% weight in medical devices and nearly 25% in CXO, including 12 AI medical and brain-computer interface concept stocks [3][8] - For those interested in Hong Kong stock medical opportunities, the Hong Kong Stock Connect Medical ETF (159137) is highlighted as a high-elasticity T+0 tool, focusing on medical innovation and gathering core leaders in various medical fields [3][8]

Group 1 - The core viewpoint of the news highlights the performance of the medical innovation sector, with the China Securities Medical and Medical Device Innovation Index showing mixed results among its constituent stocks, led by Hualan Biological at a 0.90% increase [1] - The Medical Innovation ETF has seen continuous net inflows over the past six days, with a peak single-day net inflow of 40.54 million yuan, totaling 84.99 million yuan and an average daily net inflow of 14.17 million yuan [1] - Central China Television announced that Galaxy General Robotics will be the designated humanoid robot for the 2026 Spring Festival Gala, marking a significant milestone for the company established in May 2023, which focuses on a wide range of applications including retail, industrial, medical, and cultural tourism [1] Group 2 - The China Securities Medical and Medical Device Innovation Index consists of 30 publicly listed companies with strong profitability, growth potential, and research innovation capabilities, reflecting the overall performance of the medical and medical device sector [2] - As of December 31, 2025, the top ten weighted stocks in the index include WuXi AppTec, Hengrui Medicine, Mindray Medical, and others, collectively accounting for 63.75% of the index [2] Group 3 - The current medical device sector is at a turning point, with performance recovery expected in 2026, driven by new technologies such as AI in healthcare, brain-machine interfaces, and surgical robots, leading to a continuous revaluation of innovative products with global competitiveness [1]

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4] Core Insights - The report highlights the potential acceleration of the surgical robot industry following the release of the service pricing guidelines by the National Medical Insurance Administration, which clarifies the pricing structure for surgical robot services and consumables [3][18] - The report emphasizes the importance of innovation in the pharmaceutical sector, noting that the industry has completed a transition from old to new growth drivers, particularly in innovative drugs, which are expected to continue to perform well in 2026 [46][47] - The report suggests a focus on sectors such as innovative drugs, AI medical technology, and brain-computer interfaces, which are anticipated to see significant advancements in 2026 [46][48] Summary by Sections Market Performance - From January 19 to January 23, the pharmaceutical index decreased by 0.39%, with an excess return of 0.23% relative to the CSI 300 index. The market was relatively stable, with a notable increase of 1.26% on Friday, driven by themes like brain-computer interfaces and AI medical technology [5][27] - A total of 330 stocks rose while 137 fell during the week, with notable gainers including *ST Changyao (+70.37%) and Hualan Biological (+32.21%) [27][28] Surgical Robot Industry - The surgical robot market is expected to benefit from the new pricing guidelines, which will enhance the clinical application of surgical robots and promote a sustainable business model [3][18] - The domestic laparoscopic robot market is projected to grow significantly, with a compound annual growth rate (CAGR) of 29.3% from 2024 to 2030 [9][15] Investment Recommendations - The report recommends focusing on strong fundamentals and well-adjusted innovative drug stocks, including companies like Xinlitai, Zexing Pharmaceutical, and Hengrui Medicine, as well as medical technology firms like Yuyue Medical and Alibaba Health [5][49] - It also suggests monitoring companies involved in the export of CXO services and those with stable operations and low valuations that are expected to see fundamental changes in 2026 [5][46] Future Outlook - The report anticipates that the pharmaceutical industry will continue to improve marginally in 2026, driven by technological innovation and performance recovery in traditional sectors [46][47] - Key areas of focus include innovative drugs, AI medical technology, and the aging population's healthcare needs, which are expected to drive demand [46][48]

国家知识产权局近日发布中国2025年知识产权情况，截至2025年底，中国国内发明专利有效量达到532 万件，每万人口高价值发明专利拥有量达到16件。专利密集型产业增加值占GDP比重升至2024年的 13.38%，超额完成知识产权"十四五"规划预期目标。2025年，全国共授权发明专利97.2万件，实用新型 专利146.1万件，专利复审和无效结案9.6万件。截至2025年底，全球前5000个品牌中，中国品牌价值达 1.81万亿美元，位居全球第二。 知识产权，是"基于创造成果和工商标记依法产生的权利的统称"，最主要的三种知识产权是著作权、专 利权和商标权，其中专利权与商标权也被统称为工业产权。"每万人口高价值发明专利拥有量"是国 家"十四五"规划中衡量创新产出的一个重要指标。设置这个指标主要是强化专利的质量导向，引导发明 专利从追求数量向提高质量转变。 截至2025年底，中国国内高价值发明专利拥有量达到229.2万件，占国内有效发明专利总量的比重达到 43.1%，较"十三五"末提高2.9个百分点。这表明中国专利结构正在向优转变，技术含量更高、市场价值 更高、权利状态更加稳定的发明专利占比不断提升。同时，高价值发明专 ...